Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Exploratory, Randomized, Double-blind, Parallel-group Study of ONO-8577 Compared to Combination of Solifenacin Succinate/ Mirabegron for Overactive Bladder

NCT03106623 is registered in ClinicalTrials.gov with Ono Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03106623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03106623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Exploratory, Randomized, Double-blind, Parallel-group Study of ONO-8577 Compared to Combination of Solifenacin Succinate/ Mirabegron for Overactive Bladder
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
April 7, 2017
Completion date
September 26, 2017
Enrollment
207 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder